Targeting Gastrointestinal Cancers: Keymed’s Innovative Approach

Keymed Biosciences Inc. (HKEX: 02162) is making meaningful strides in oncology with it’s antibody-drug conjugate (ADC) program. Their lead candidate, CM518D1, has recently entered Phase I/II clinical trials in China for the treatment of advanced solid tumors.this growth underscores Keymed’s commitment to addressing unmet medical needs in cancer therapy.

CM518D1: A Precision Strike Against CDH17-Expressing Tumors

CM518D1 represents a novel approach to cancer treatment by targeting CDH17, a protein highly expressed in various gastrointestinal cancers. CDH17, or Cadherin-17, belongs to the cadherin superfamily and plays a crucial role in tumor invasion and metastasis, making it an attractive therapeutic target.Colorectal cancer, gastric cancer, pancreatic cancer, and esophageal cancer are among the gastrointestinal cancers that highly express CDH17.

the ADC mechanism of CM518D1 allows for the targeted delivery of cytotoxic payloads directly to tumor cells. By combining a monoclonal antibody specific to CDH17 with a potent chemotherapy drug, CM518D1 aims to maximize efficacy while minimizing systemic toxicity. Preclinical studies have demonstrated the drug’s potent cytotoxic activity,bystander effect,and plasma stability. Furthermore, CM518D1 has shown remarkable anti-tumor efficacy in multiple solid tumor xenograft models, with a favorable safety profile and a wide therapeutic window in toxicological evaluations.

“CM518D1 demonstrates remarkable anti -tumor efficiency in multiple models of xenogreffe of solid tumors, has a favorable safety profile and a large therapeutic margin in toxicological evaluations.”

Clinical Trials and Future Prospects

Keymed is currently conducting Phase I/II clinical trials in China to evaluate the safety, tolerability, and preliminary efficacy of CM518D1 in patients with advanced solid tumors. These trials are crucial for determining the optimal dosage and identifying potential side effects. The ultimate goal is to develop a more precise, effective, and safer therapeutic option for patients with gastrointestinal cancers worldwide.

Keymed’s Advanced ADC Platform: A Foundation for Innovation

Keymed’s proprietary ADC platform is at the heart of its innovative drug development efforts. This platform enables the design of next-generation ADCs with novel payloads, hydrophilic linkers, and modified antibodies. These features are optimized for drug stability,release,enhanced binding,and improved pharmacokinetics.

To support the development and clinical research of ADCs, Keymed has established GMP-compliant facilities for the production of both drug-free and drug-loaded ADCs. This infrastructure positions Keymed as a leader in ADC therapeutics, enabling the company to address the unmet medical needs of patients globally.The global ADC market is projected to reach $29.4 billion by 2028, growing at a CAGR of 23.7% from 2021,according to a report by Global Market Insights,Inc.

About Keymed Biosciences

Keymed Biosciences Inc. (HKEX: 02162) is a biotechnology company focused on addressing unmet clinical needs by providing patients with innovative, affordable, and high-quality treatments in China and abroad. Founded by medical and scientific experts with extensive experience in translating scientific breakthroughs into marketable products,Keymed is committed to advancing healthcare through cutting-edge research and development.